Literature DB >> 35449383

Prescribing of anticoagulation for atrial fibrillation in primary care.

Kathryn A Martinez1, Mark H Eckman2, Matthew A Pappas3, Michael B Rothberg3.   

Abstract

Atrial fibrillation (AF) is common in primary care patients. Many patients who could benefit from anticoagulation do not receive it. The objective of this study was to describe anticoagulation prescribing by primary care physicians. We conducted an observational study in the Cleveland Clinic Health System among patients with AF and ≥ 1 primary care appointment between 2015 and 2018 and their physicians. We estimated differences in the odds of an eligible patient receiving anticoagulation versus not and a DOAC versus warfarin using two mixed effects logistic regression models, adjusted for patient sociodemographic factors, history of falls or dementia, and CHA2DS2-VASc and HAS-BLED scores. We categorized physicians into prescribing tertiles, based on their adjusted prescribing rate, which we included as predictors in the models. Among 5253 patients, 47% received anticoagulation. Of those, 56% received a DOAC. CHA2DS2-VASc and HAS-BLED scores were not associated with anticoagulation prescription. Black race was negatively associated with receiving anticoagulation overall (aOR:0.71; 95%CI:0.56-0.89) and with prescription for a DOAC (aOR:0.65; 95%CI:0.45-0.93). Among 195 physicians, the anticoagulation prescribing rate ranged from 27% to 57% and DOAC rates ranged from 34% to 69%. Physician prescribing tertile was associated with odds of a patient receiving anticoagulation overall (aOR:1.51; 95%CI: 1.13-2.01 for the highest versus lowest tertile), but not DOAC prescriptions. When prescribing anticoagulation, physicians appear not to consider risk of stroke or bleeding but patient race is an important determinant. Seeing a physician with a high anticoagulation prescribing rate was strongly associated with a patient receiving it, suggesting a lack of individualization.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anticoagulants; Clinical decision making; Healthcare disparities; Primary care physicians; Quality of health care

Year:  2022        PMID: 35449383     DOI: 10.1007/s11239-022-02655-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  39 in total

1.  Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry.

Authors:  Michał Mazurek; Eduard Shantsila; Deirdre A Lane; Andreas Wolff; Marco Proietti; Gregory Y H Lip
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sandeep R Das; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Carmen R Isasi; Monik C Jiménez; Suzanne E Judd; Brett M Kissela; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David J Magid; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Wayne Rosamond; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2015-12-16       Impact factor: 29.690

3.  The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients.

Authors:  Paul Angaran; Paul Dorian; Mary K Tan; Charles R Kerr; Martin S Green; David J Gladstone; L Brent Mitchell; Carl Fournier; Jafna L Cox; Mario Talajic; Peter J Lin; Anatoly Langer; Lianne Goldin; Shaun G Goodman
Journal:  Can J Cardiol       Date:  2015-10-15       Impact factor: 5.223

4.  Warfarin use in atrial fibrillation: A random sample survey of family physician beliefs and preferences.

Authors:  A A Pradhan; M A H Levine
Journal:  Can J Clin Pharmacol       Date:  2002

Review 5.  Underuse of oral anticoagulants in atrial fibrillation: a systematic review.

Authors:  Isla M Ogilvie; Nick Newton; Sharon A Welner; Warren Cowell; Gregory Y H Lip
Journal:  Am J Med       Date:  2010-07       Impact factor: 4.965

6.  Newly detected atrial fibrillation and compliance with antithrombotic guidelines.

Authors:  Nicole L Glazer; Sascha Dublin; Nicholas L Smith; Benjamin French; Lisa A Jackson; Jennifer B Hrachovec; David S Siscovick; Bruce M Psaty; Susan R Heckbert
Journal:  Arch Intern Med       Date:  2007-02-12

7.  Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use.

Authors:  Julian P Casciano; Daniel E Singer; Winghan Jacqueline Kwong; Eben S Fox; Bradley C Martin
Journal:  Am J Cardiovasc Drugs       Date:  2012-10-01       Impact factor: 3.571

8.  Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated.

Authors:  David J Gladstone; Esther Bui; Jiming Fang; Andreas Laupacis; M Patrice Lindsay; Jack V Tu; Frank L Silver; Moira K Kapral
Journal:  Stroke       Date:  2008-08-28       Impact factor: 7.914

9.  Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: evidence of continuing low use despite consideration of stroke and bleeding risk.

Authors:  Gregory Reardon; Winnie W Nelson; Aarti A Patel; Tommy Philpot; Marjorie Neidecker
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

10.  Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices.

Authors:  Edward Ewen; Zugui Zhang; Teresa A Simon; Paul Kolm; Xianchen Liu; William S Weintraub
Journal:  Vasc Health Risk Manag       Date:  2012-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.